A novel mechanism of ferroptosis surveillance offers promising therapeutic avenues for breast and prostate cancers

Published in Cell on May 23, 2023 [1], this paper demonstrates that Membrane Bound O-Acyltransferase Domain Containing 1 (MBOAT1) and Membrane Bound O-Acyltransferase Domain Containing 2 (MBOAT2) can serve as novel targets for cancer treatment, offering new possibilities for treating cancers with specific genetic backgrounds (Fig. 1). Interestingly, while MBOAT1 and MBOAT2 seemingly suppress ferroptosis through a shared biochemical pathway, their regulation by sex hormone signaling differs, implying distinct biological functionalities. [...]AR antagonists could increase the sensitivity of AR-positive prostate cancer cells to ferroptosis by downregulating MBOAT2 directly. [...]the study reveals that MBOAT1 and MBOAT2 can inhibit ferroptosis through phospholipid remodeling independently of GPX4.